Gianpietro Dotti, MD (IMAGE)
Caption
“CAR-T cells produced in the lab for reinfusion can be extremely different from one patient to another and the lack of certain types of cells in the end product can significantly reduce the capacity of these cells to persist long term,” said Gianpietro Dotti, MD, professor of microbiology and immunology at UNC School of Medicine and co-leader of the UNC Lineberger immunology research program. “Our study demonstrates that the addition of the drugs we have identified during the re-engineering process allows the preservation of a critical cell subset responsible for long-term persistence.”
Credit
UNC Lineberger Comprehensive Cancer Center
Usage Restrictions
None
License
Original content